Eli Lilly, the world's largest pharmaceutical company by market capitalization, increased its net income by one and a half times in the fourth quarter of 2025 and raised revenues by 43% due to high demand for diabetes and weight loss medications.
According to the company's press release, its net income for October to December was $6.64 billion, or $7.39 per share, compared to $4.41 billion, or $4.88 per share, for the same period a year earlier.
Revenue increased by 43% to $19.29 billion against a forecast of $18.01 billion.
The best-selling drug in the last quarter was Mounjaro, used for weight reduction - sales of this drug soared more than twofold to $7.41 billion. Sales of Zepbound (a similar drug) increased 2.2 times to $4.26 billion.
This year, Eli Lilly expects adjusted earnings in the range of $33.5-35 per share with revenue of $80-83 billion. Analysts' forecast anticipates revenue of $77.7 billion.
Over the past 12 months, the company's market capitalization has increased by 19.2% to $987.1 billion. It won't be long before it reaches $1 trillion.
